SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy
Latest Information Update: 16 May 2025
At a glance
- Drugs 225Ac PSMA R2 (Primary) ; Gallium 68 PSMA R2
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms SatisfACtion
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Planned number of patients changed from 200 to 70.
- 05 Mar 2025 Planned number of patients changed from 70 to 200.
- 27 Feb 2025 Planned End Date changed from 18 Dec 2029 to 5 Nov 2029.